Publication Cover
Amyloid
The Journal of Protein Folding Disorders
Volume 13, 2006 - Issue 4
839
Views
202
CrossRef citations to date
0
Altmetric
Original

Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis

, &
Pages 236-249 | Published online: 06 Jul 2009
 

Abstract

Objective. Rate-limiting transthyretin (TTR) tetramer dissociation and monomer misfolding enable misassembly into numerous aggregate morphologies including amyloid, a process genetically linked to and thought to cause amyloid pathology. T119M TTR trans-suppressor subunit inclusion into tetramers otherwise composed of disease-associated subunits ameliorates human amyloidosis by increasing the tetramer dissociation barrier. Diflunisal binding to the 99% unoccupied L-thyroxine binding sites in TTR also increases the tetramer dissociation barrier; hence, we investigated the feasibility of using diflunisal for the treatment of human TTR amyloidosis using healthy volunteers.

Methods. Diflunisal (125, 250 or 500 mg bid) was orally administered to groups of 10 subjects for 7 days to evaluate serum diflunisal concentration, diflunisal binding stoichiometry to TTR, and the extent of diflunisal imposed TTR kinetic stabilization against urea- and acid-mediated TTR denaturation in human serum. The rates of urea-mediated tetramer dissociation and acid-mediated aggregation as a function of diflunisal concentration were also evaluated in vitro, utilizing physiologically relevant concentrations identified by the above experiments.

Results. In the 250 mg bid group, 12 h after the 13th oral dose, the diflunisal serum concentration of 146 ± 39 μM was sufficient to afford a TTR binding stoichiometry exceeding 0.95 ± 0.13 (≈1.75 corrected). Diflunisal binding to TTR at this dose slowed urea-mediated dissociation and acid-mediated TTR aggregation at least, threefold (p < 0.05) in serum and in vitro, consistent with kinetic stabilization of TTR.

Conclusion. Diflunisal-mediated kinetic stabilization of TTR should ameliorate TTR amyloidoses, provided that the nonsteroidal anti-inflammatory drug liabilities can be managed clinically.

Abbreviations
FAC=

familial amyloid cardiomyopathy;

FAP=

familial amyloid polyneuropathy;

TTR=

transthyretin

Abbreviations
FAC=

familial amyloid cardiomyopathy;

FAP=

familial amyloid polyneuropathy;

TTR=

transthyretin

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.